Bristol Myers Squibb has received approval from the US Food and Drug Administration (FDA) for its cancer treatment Opdivo Qvantig. The treatment, which is administered via a subcutaneous injection, was shown to have similar efficacy and safety as an existing intravenous treatment in patients with advanced kidney cancer.
According to medical oncologist Saby George, the faster administration of Opdivo Qvantig may allow patients to choose alternative treatment methods or receive treatment closer to home. The FDA approval is based on results from a Phase 3 trial that compared Opdivo Qvantig to the existing treatment.
The trial found non-inferior pharmacokinetic exposures and comparable safety profiles between the two treatments. With Opdivo Qvantig, patients can now receive treatment in just three-to-five minutes, making it a more flexible option for those with busy schedules or preferences for local care.
Source: https://www.marketwatch.com/story/bristol-myers-squibb-receives-fda-approval-for-cancer-treatment-2a610f4b?mod=dj-newswires